| Followers | 1 |
| Posts | 292 |
| Boards Moderated | 0 |
| Alias Born | 05/14/2020 |
Saturday, June 06, 2020 1:08:04 PM
also had a conference Thursday. If the study wasn't ready two business days sooner, I don't think it's hype to add a bullet point on timing. But how they handled this news might be a good sign that galid. is further along than we think.
Hope this isn't an echo chamber because we all own the stock. I really do feel like some criticism is warranted of late. The strength of the company seems to be their scientists not their leadership. This at least bodes well for the factor D pipeline.
I will take a lot of my criticism back if they are further along on galid then they seem to be. You just have to move fast on that front.
Here's hoping we get back to $5 by end of next week!
Hope this isn't an echo chamber because we all own the stock. I really do feel like some criticism is warranted of late. The strength of the company seems to be their scientists not their leadership. This at least bodes well for the factor D pipeline.
I will take a lot of my criticism back if they are further along on galid then they seem to be. You just have to move fast on that front.
Here's hoping we get back to $5 by end of next week!
Recent BCRX News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/19/2026 08:07:43 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/18/2026 08:48:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/15/2026 08:08:01 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/13/2026 05:06:28 PM
- BioCryst to Present New Real-World Evidence Underscoring the Ongoing Burden of Pediatric Hereditary Angioedema at ISPOR 2026 • GlobeNewswire Inc. • 05/13/2026 11:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/06/2026 08:06:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:08:17 AM
- BioCryst Reports First Quarter 2026 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/05/2026 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 11:06:53 AM
- BioCryst Announces European Licensing Agreement with Irish Affiliate of Neopharmed Gentili for Navenibart in Hereditary Angioedema • GlobeNewswire Inc. • 05/04/2026 11:00:00 AM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 04/29/2026 09:02:16 PM
- BioCryst to Present at Upcoming Investor Conferences • GlobeNewswire Inc. • 04/28/2026 11:00:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/23/2026 08:10:57 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/23/2026 08:02:30 PM
- BioCryst to Report First Quarter 2026 Financial Results on May 6 • GlobeNewswire Inc. • 04/15/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/07/2026 08:24:44 PM
- BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer • GlobeNewswire Inc. • 04/06/2026 11:00:00 AM
- BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 04/03/2026 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 08:02:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/20/2026 03:36:47 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/18/2026 08:11:09 PM
